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Abstract: Objective: Treatment of wounds difficult to heal concerns 50% of the elderly population in 
Italy and is therefore a relevant social burden. The present study shows how the treatment with autolo-
gous leuco-platelets reduces the healing time of wounds improving the functional recovery.  
Patients and Methods: Patients (n=100) with ulcers of the legs were divided in two groups: 1) 50 patients 
treated with conventional therapies; 2) 50 patients treated with autologous leuco-platelet concentrate 
(LPC) and hyaluronic acid (HIAFF, Hyalofill-F
®
) as a scaffold. 
Results: After 2 months, a 49% reduction in wound area was observed in the second group and in about 
65% wound reduction was achieved in 15 days (4 LPC dressings). In contrast, patients treated by conven-
tional therapies, showed a longer healing time and a greater percentage of failures. Morphometric analysis 
of biopsy samples obtained from the edge as well as from the bottom of the lesions obtained from the 
LPC group, detected an abundant presence of neoformed capillaries, characterized by a cubic, "reactive 
endothelium", close to the site of LPC infiltration.  
Conclusions: These results suggest that healing was promoted not only by limiting bacterial infections 
but also by the release of chemotactic and proangiogenic factors from leukocytes and platelets, improving 
the neoformation of capillaries. 
Keywords: Wound healing, leuco-platelet concentrate, hyaluronic acid, morphometry, neoangiogenesis. 
INTRODUCTION 
 Difficult to heal wounds [1] frequently occur in the eld-
erly and those with vascular or metabolic diseases (e.g. dia-
betes or obesity). Since population aging is a global phe-
nomenon the presence of difficult to treat wounds is a world-
wide social problem [2]. Most patients suffer from marked 
reductions of quality of life, including pain, physical discom-
fort, functional limitations, as well as psychological distress 
[3]. Most patients complain about the additional burden of 
treatment. 
 The problem of difficult to heal wounds is of great social 
relevance in our country where it involves >50% of the eld-
erly population [4]. The treatment of difficult wounds re-
quires in most cases 3 day dressings/week, involving the 
displacement of specialists or the patient himself, often need-
ing the involvement of several skills (vascular surgeon and 
plastic surgeon, diabetologist, angiologist, infection special-
ist, nephrologist, etc) [5]. The functional recovery achieved  
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by the intervention with 'integrated' polyspecialist skills, 
seems to have a favourable impact on the level of collective 
social costs, besides the 'Quality of Life' of the patient and 
his family [5-7].  
 Numerous studies in the literature have evidenced that 
the use of the advanced wound dressings allows to reach the 
best clinical and economic results in the process of recovery 
of difficult wounds. The advanced wound dressing assures a 
shorten time of treatment and, as a consequence, it requires a 
smaller number of applications compared with the traditional 
medications [8].  
 Considerable progress has been achieved after the intro-
duction of regenerative medicine methods which propose to 
accelerate the restitutio ad integrum of damaged tissues, 
adding cells to biopolymers matrices capable to recruit and 
stimulate the differentiation of precursors, in order to repair 
and revascularise damaged tissues [9-11].  
 Biopolymers provide a mechanical support for the migra-
tion and cell proliferation. In contact with the wound, the 
three-dimensional fibres of hyaluronic acid that constitute a 
Hyalomatrix, form a resorbable scaffold that accelerates the 
migration of cells involved in dermal reparative processes. 
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The addition of autologous cells, as described in detail be-
low, triggers a series of processes that should lead to the 
formation of new blood vessels and new tissue, structurally 
and functionally analogous to the damaged tissue [12]. 
 Among the various proposed preparations, the best, in 
terms of effectiveness and economy is the one that employs 
the platelet gels [9]. We proposed a therapeutic strategy to 
treat difficult wounds, using matrices of biopolymers to re-
place the dermis acting as mechanical support, seeded with 
autologous leukocytes and platelets. Several studies have 
been performed evaluating the role of platelet enriched 
preparations, especially for their high content of factors pro-
moting soft tissue healing and neovascularization [13]. Most 
of them deal with animal experimental models [14, 15] 
whereas our results are based on patients.  
METHODS 
 The study program was carried out in several distinct 
phases: 
Selection and Recruitment of Patients 
 Patients were selected among those treated at Surgical 
Sciences Dept. (Policlinico Umberto I, School of Medicine, 
Sapienza University of Rome). Patients (n = 100) with ulcers 
of the legs were divided in two groups, locally treated with 
conventional therapies or with autologous leuco-platelet 
concentrate (LPC) and hyaluronic acid (HA) as a scaffold, 
and followed up until complete healing of the lesions. All 
patients, suffering of arterial hypoperfusion of lower limb, 
had extended cutaneous and soft tissues loss of the extremi-
ties with well controlled pain.  
 Exclusion criteria were steroid drugs. Before starting 
treatment, patient informed consent was obtained. The study 
protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in approval by the insti-
tution's research review committee. 
 Photographic documentation, assessing ulcer and perile-
sional tissue state (exudate, infection and necrosis) was re-
corded. The following parameters: localization, size, time of 
onset, were also recorded. Sizes of the ulcers, surgical treat-
ment and outcome are depicted in Table 1. 
Autologous Blood Collection and Preparation of the LPC 
 A multi-cell separator Haemonetics MCS + discontinu-
ous flow 
®
 (Haemonetics Corp., Braintree, MA, USA) was 
used to obtain blood components. A concentrate with a high 
number of leukocytes and platelets was obtained after 6 cy-
cles of the average length of 76 min, using a disposable cir-
cuit for the collection of stem cells (Cod.971E).  
LPC 
 The average platelet count was 6691 x 10/μl, producing 
a high yield, considering an average pre-apheresis count of 
380 x 10/l. The average pre-apheresis white blood cell 
count was 7.7 x 10/l, while the LPC count was 54.7 x 
10/l. Of particular relevance this amount of leukocytes was 
obtained without any stimulation of the patient with growth 
factors (G-CSF), as was previously done by other groups, in 
order to improve the yield of mobilized peripheral blood 
cells by apheresis [16-18]. Figure 1 depicts the different 
phases of gel preparation. Blood counts performed during the 
following checks did not show any significant variations. 
 The LPC was stored at +4°C, while the plasma was im-
mediately frozen at -80 °C and then thawed at + 4°C for 8-12 
h to obtain the cryoprecipitate by centrifugation. The LPC 
was subsequently mixed with the cryoprecipitate in equal 
volume, to enrich it with fibrinogen and other proteins of the 
extracellular matrix. The enriched concentrate was divided 
into several aliquots and stored at -40°C. The gel was ob-
tained by activating platelets by autologous thrombin, ob-
tained from serum, using Sarstedt vacutainer tubes. Serum 
was mixed with calcium gluconate, with 2:1 ratio, and added 
to the enriched LPC to form the gel in a few minutes. To 
increase the consistency, the gel was placed in a “Petri” cap 
containing a sheet of hyaluronic acid (HIAFF, Hyalofill-F 
®
). 
Treatment of Wounds  
 Every patient, after wound swab for microbiological in-
vestigations and cleansing, was subjected to infiltration in 
areas of necrosis. Curettage and debridement were performed 
to remove the necrotic tissue. The T.I.M.E. concept (Tissue. 
Infection. Moisture imbalance. Epidermal margin) was usually 
applied. It summarizes the four main components of wound 
bed preparation: Tissue management, Control of infection and 
inflammation, Moisture imbalance, Advancement of the 
epithelial edge of the wound. Initially the local treatment 
involved surgical or enzymatic debridement and anti-
microbial therapies using iodoform gauze. Hyaluronic acid 
was applied on the ulcers as soon as possible. Secondary 
dressing with silver sulfadiazine was used for all the patients. 
Gel containing autologous leuco-platelet concentrate using 
hyaluronic acid (Hyalofill-F 
®
) as a scaffold, and Connet-
tivina gauze 
®
 as a secondary dressing, was then directly 
applied to the lesion in the form of gel. A part of the prepara-
tion not conjugated with calcium gluconate and thrombin, 
was infiltrated directly on the edge of the lesion, although 
necrotic or undermined, and at the bottom of the ulcer. Dur-
ing the dressing the direct contact of blood component with 
aggressive products such as hydrogen peroxide, betadine 
solution and/or potassium permanganate was avoided. Ap-
plications were stopped if Pseudomonas A infection occurred 
or the lesion was well underway toward recovery. The re-
sponse to the therapy has been estimated taking into account 
the reduction in ulcer area and depth, and the presence of 
regenerative tissue. Image J software (NIH, USA) has en-
abled us to calculate the total area of the wound and granula-
tion tissue, taking advantage of photographic documentation. 
Assessment of Neovascularization and Morphometric 
Analysis  
 Biopsy samples were collected periodically in order to 
assess the formation of new vessels by morphometric analy-
sis and establish a temporal correlation with the time of re-
covery. During every curettage, biopsies were obtained from 
the edge of the lesion, even if necrotic or undermined, and 
from the bottom of the ulcer. Samples were fixed with 10% 
buffered formalin, then embedded in paraffin. Sections (2 
μm) were then deparaffinised with xylene and hydrated 
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through washes of ethanol and stained with haematox-
ylin/eosin. Morphometric analysis was performed using a 
Leica DM4000B microscope. For each sample neovessels 
were counted and related to the section area expressed in μm 
[2], as quantified by IAS2000 software.  
Immunohistochemical Analysis 
 Wound samples obtained as described above, were fixed 
overnight in 10% neutral-buffered formalin, dehydrated and 
embedded in paraffin. Microtome sections (2 μm thick) were 
rehydrated and incubated for 15 min in 0.3% H2O2-methanol 
to block endogenous peroxidases. After extensive washing in 
PBS, sections were incubated with Ab anti-CD34 (Leica 
Biosystems, Novocastra, Surgipath cat. NCL-L-END),  or 
with Ab anti-CD31 (Sino Biological cat. n.10148-H08H) or 
Antibody anti-VEGF (Vascular Endothelial Growth Factor) 
(Immunological Sciences AB-90040), rewashed and treated 
with a secondary antibody (LSAB+System-HRP, K0690, 
DAKO, Glostrup, Denmark). Sections were then incubated 
with DAB (3,3'-diaminobenzidine) and then extensively 
washed. The specificity of the reaction was assessed by in-
cubating adjacent sections with isotype-matched irrelevant 
antibodies instead of the primary antibody. Images were ob-
tained with an Olympus digital camera n.C5060 Wide Zoom 
on Leica Leitz DMRB Microscope (Wetzlar, Germany).  
 Usually 1 h before each dressing, which may consist of 
tissue removal (debridement) necrosectomy we administer 
analgesics because this process may elicit pain (pain or dis-
tress). 
Statistical Analysis 
 Statistical analysis to evaluate the improvement of clini-
cal results between groups was conducted using a chi-square 
or Fisher exact test, as shown in Tables 1 and 2; p<0.05 two-
tailed was considered significant. 
RESULTS 
 Two groups of 50 patients each were included in this study 
in order to assess the effectiveness of autologous LPC com-
pared to conventional therapies to promote healing of difficult 
wounds. In patients treated with a scaffold of hyaluronic acid 
supplemented with LPC we observed that 38 patients showed 
a reduction of the ulcer area of at least 25% after 2 to 4 LPC 
applications, over a period of 2-4 weeks, as shown in Table 
1b. In the same period we obtained the wound cleansing and a 
marked reduction in pain even during the medication (NRS: 
Numerical Rating Scale from 8 to 3). In the group treated with 
conventional local treatment only 24 patients (19 M and 5 F) 
showed a 25% reduction of ulcer area (Table 1a). Over a pe-
riod of 8 weeks we observed a superficialization of the ulcer 
bottom, after 2-8 LPC applications and a reduction of 50% of 
the wound volume; >60% of these patients achieved this result 
after 4-6 LPC dressings (Figs. 2, 3). In a 4 week period 8 pa-
tients showed only fluctuating improvements but had fever 
 
Fig. (1). Autologous blood collection and leuco-platelet concentrate 
preparation. a,b)withdrawal by multi-cell separator Haemonetics 
MCS + discontinuous flow. Serum plus calcium gluconate was 
added to the enriched leuco-platelet concentrate preparation to form 
the gel and to increase its consistency; the gel was placed in a 
“Petri” cap containing a sheet of hyaluronic acid (c-e). 
 
Fig. (2). a,b) Debridement of ischemic lesion of the leg; c,d) 
Hyaluronic acid used as dermal substitute (Hyalofill-F, HyaloMa-
trix) and treatment with infiltration of PRP (Platelet Rich Plasma); 
e,f) Regenerative and healing outcome: reduction of the area of the 
lesion (new epidermal tissue of the borders and growth of the bot-
tom of the ulcer) until complete healing. 
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with humid gangrene and had to undergo amputation: 6 of 
them have been treated with conventional therapy and 2 with 
the LPC. In two LPC-treated cases it was necessary to ampu-
tate above the knee (AK: see Table 2) for the worsening clini-
cal, systemic and local conditions.  
 Major amputations were necessary in 11 other cases: 9 
patients in the "conventionally treated" group and 2 patients 
of the “LPC treated” group for the appearance of septic fever 
and gangrene beyond 4 weeks. Fourteen segmentary amputa-
tions occurred in both groups, as shown in Table 2a and Ta-
ble 2b.  
 We also successfully treated those patients at high risk of 
"major" amputation for large necrotic lesions and severe 
limb ischaemia (ABI, Ankle Brachial Index < 0.5): we lim-
ited amputations to metatarsophalangeal joints maintaining 
functional autonomy (Fig. 2).  
 So the wound healing and the limb salvage was obtained 
in 81 patients; 46 in the “LPC-treated” group and 35 in the 
“conventional” one: healing was achieved between 6 and 22 
months; the median time to heal for all wounds was 96 days 
[interquartile range (IQR) = 84-106]; all the third quartile is 
composed of patients treated with conventional therapy.  
 In the LPC treated group the wound healing was obtained 
after 6 - 22 weeks; the frequency of dressings was from 3 
and 15 days, during the treatment. More than half of the  
patients recovered complete functional capacity within the 
first 12 months (28 patients).  
 The results, compared with those obtained with a control 
group of 50 patients matched for sex, age and pathogenesis, 
who were treated with drugs, including bioactive ones (HA) 
without autologous LPC, showed a longer healing time with 
a greater loss of substance and a higher number of major 
amputations (15 vs 4), with a lower "limb salvage" percent-
age (72 vs 92%) (Tables 2a, 2b). Statistical analysis con-
ducted with chi-square or Fisher exact test showed a signifi-
cant correlation between an improved clinical result and the 
autologous LPC treatment (Tables 1, 2). 
 The histological analysis of biopsy samples (Fig. 4) 
showed abundant newly formed capillaries, characterized 
by a cubic, "reactive endothelium" near the site of LPC 
infiltration, with an average number of 16 neocapillar-
ies/mm
2
 (Figs. 4A-C). Morphometric techniques applied to 
sequential tissue samples obtained from the edges of ulcers 
showed a rise in neo-angiogenesis in patients treated with 
the autologous LPC compared with those who received 
traditional therapy. In Fig. (4A, B, C) neovessel formation 
at the ulcer border is depicted: note the rounded agglomer-
ates, devoid of lumen, and several surrounding structures 
 
Fig. (3). Severe limb ischaemia treated with femoropopliteal bypass 
and wound care: transmetatarsal amputation, debridement, use of 
leuco-platelet concentrate and wound dressings (H.A.). Heal as 
final result. a) Post-traumatic ischaemic limb; b) Surgical explora-
tion of damaged tissues; c) Bone stabilization and autologous sa-
phenous vein graft; d) NPWT Negative Pressure Wound Therapy. 
 
Fig. (4). Transmitted light images of haematoxylin-eosin stained 
sections of ulcer biopsy samples and immunohistochemical analy-
sis A) abundant capillary formation in the close proximity of the 
injected leukocytes (100x); B) a representative count of neocapil-
laries (100x); C) Clusters of neoformed vases in the healing ulcers 
(200x); D) EPC (Endothelial Precursor Cells) lining neoformed 
capillaries are stained by an anti-CD34 Antibody (200x); E) EPC 
stained by an anti-CD31 Antibody are present in capillaries under-
going cavitation (400x); F) An abundant presence of Vascular En-
dothelial Growth factor (VEGF) was detected in the LPC infiltrated 
lesion (200X).  
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where cavitation, critical to establish a blood flow, is taking 
place. Note the cubic appearance of endothelial cells within 
the vessels taking shape. The endothelial precursor cells 
(EPC) of the neo-vessel are interconnected and are ar-
ranged to establish an apical-basal polarity, according to 
Datta et al. [19]. EPCs involved in vessel regeneration are 
stained by an anti-CD34 Ab (Fig. 4D) in the early stages 
and by an anti-CD31Ab (Fig. 4E) in later forms. Further-
more, an abundant presence of VEGF was detected in the 
area of the lesion very close to neovessels and the LPC 
infiltrate (Fig. 4F). 
 Our data show that the presence of neoangiogenesis cor-
relates with clinical outcome preceding wound healing.  
DISCUSSION  
 The severity of the disease, the costs incurred both in the 
time of hospitalization, and the subsequent rehabilitation, has 
Table 1a Patients treated with conventional local treatment §.
N° pts -Gender Age Diabetes Size range (cm2)* Wound Treatment Area of the lesion 
reduced by 25% (**) 
36M 45-84 12 8-112 17 pts (47.7%) 
14F 36-78 3 3-91 
Weekly debridement 
and 
twice-daily 
dressing changes 
5 pts (35.7%) 
Sizes before(*) and after (**) 2-4 weeks of local treatment;  
Pts = patients, M = males, F = females
 
Table 1b Patients treated with leuco-platelet concentrate §.
N° pts -Gender Age Diabetes Size range (cm
2
)* Wound Treatment 
Area of the lesion 
reduced by 25% (**) 
36M 36-84 9 12-96 28 pts (77.7%) 
14F 41-76 4 3-84 
After debridement 
weekly LPC applica-
tion and infiltrations 
(2-4) 
10 pts (71.4%) 
  
Sizes before(*) and after (**) 2-4 weeks of local treatment;  
(§) Chi-square = 9.375, p = 0.022  
LPC = Leuco-Platelet Concentrate, Pts = patients 

Table 2a. Clinical results local treatment. 
#Patients treated with conventional local treatment. 
N° pts -Gender Age Diabetes Clinical Result Limb salvage (%)
36 M 45-84 12 
10 major amputations (7AK, 3BK) 
9 segmentary amputations 
All wounds and stumps healed
72.2 
14 F 36-78 3 
5 major amputations (5AK) 
5 segmentary amputations 
All wounds and stumps healed
71.4 
AK = Above knee, BK = Below knee
 
Table 2b. Clinical results leuco-platelet infiltration. 
 #Patients treated with leuco-platelet infiltrations.
N° pts -Gender Age Diabetes Result Limb salvage (%)
36 M  45-84  9 3 major amputations (1AK and 2 BK)  
8 segmentary amputations 
All wounds and stumps healed
91.6 
14 F  36-78  4  1 major amputation (1AK)  
6 segmentary amputations 
All wounds and stumps healed
92.8 
# Fisher exact test p = 0.044
AK = Above knee, BK = Below knee
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led researchers to explore new therapeutic options to opti-
mize the treatment of advanced ulcers of the extremities. 
Encouraging results have come from the use of stem cells 
obtained from bone marrow and/or precursors of endothelial 
cells present in peripheral blood [20-22]. Several different 
protocols have been proposed and developed in different 
trials worldwide, some of them taking advantage of bone 
marrow-derived cells, others of peripheral blood derived 
cells to induce therapeutic angiogenesis, in order to provide a 
local perfusion sufficient for wound healing. The proposed 
ways of cell administration included intra-muscular and in-
tra-arterial injection or a combination of both [23]. Consider-
ing the totality of the studies, we may conclude that a local 
supplementation of proangiogenic haematopoietic progeni-
tors consisting of immature and differentiated myelomono-
cytic cells is needed to allow the revascularization of 
ischaemic tissue [24]. Another interesting source of stem 
cells is represented by mesenchymal cells obtained from 
adipose tissue [10]. The fundamental contribution of these 
cells is not limited to the recruitment of new elements for 
vascular growth, but consists in the secretion of cytokines 
and growth factors, which promote vascular growth by 
paracrine mechanisms [25]. In this connection platelets seem 
to play a central role: activated platelets produce extremely 
high levels of Platelet Derived Growth Factor (PDGF) and 
stromal-derived factor-1 (SDF-1), also known as CXCL12, 
which induces the mobilization of CXCR4+VEGFR1+ cells, 
accelerating revascularization: the levels of these molecules 
are increased by pro-inflammatory mediators, and by altera-
tions of the extracellular matrix following mechanical forces 
and hypoxia [17, 26-28]. 
 Moreover, the literature [29-33] suggests the role of some 
cytokines in triggering a 'cascade' of events that promotes the 
expression of phenotypic characteristics of mature endothe-
lial cells in undifferentiated progenitor elements, increasing 
the availability of cell populations able to repair the endothe-
lium and thus improve vascular function [16]. Among the 
activated components of the cryoprecipitate, fibronectin, a 
glycoprotein of the extracellular matrix, promotes cellular 
adhesion and migration to the site of the lesion, forming lo-
cally the ideal "micro-environment" for the differentiation of 
endothelial cells and the formation of new capillaries. As 
reported by Asahara and coworkers [16], EPCs isolated from 
peripheral blood, seeded onto plates coated with fibronectin, 
grew with typical characteristics of endothelial cells. More 
recent studies have also identified a subpopulation of EPCs 
(CD34 +, CD45-), derived directly from peripheral blood 
monocytes, which can play a key-role in neoangiogenesis in 
vivo [34]. Our histochemical results prove the presence of 
these cells in neoforming vessels. 
 Another important aspect of platelet concentrate is the 
potential anti-bacterial effect, determined both by the pres-
ence of proteins of the HPAP (Human Antimicrobial Pep-
tides Platelet), such as fibrinopeptides A and B, thymosin 
beta-4, platelet basic protein 3, RANTES, tissue activation 
peptide, and platelet factor 4, and the higher concentration of 
leukocytes present in situ (7 times higher than in circulating 
blood). The effectiveness of the Platelet Rich Plasma was 
evaluated against Escherichia coli, Staphylococcus aureus, 
Candida albicans, as well as Cryptococcus neoformans and 
Staphylococcus MSSA and MRSA (methicillin-sensitive and 
methicillin-resistent staphylococcus aureus), with positive or 
promising results [35, 36]. The antibacterial activity, proba-
bly associated to the infiltrated preparation, suggests the 
topical use of haemocomponents, earlier, during the phase 
called "TIME". In this phase necrotic tissue, fibrin or marked 
exudation is present, favouring the development of bacterial 
colonies. Patients with diabetes are primarily affected with 
infected lesions, with 'necrotizing' evolution, involving 
tegumentary structures such as tendons and ligaments: in 
these situations it is very important to minimize the surgical 
debridement, which might irreparably compromise the func-
tions of these structures; in these cases we perform the 
cleansing with an ultrasonic dissector, to allow a faster re-
growth of the surrounding tissues and to obtain a functional 
and anatomic saving.  
 The use of stem or precursor cells has achieved impres-
sive results and has demonstrated high potentials, as empha-
sized in the literature [37], but costs represent a major limita-
tion to their extensive use and further technological devel-
opment. We have to make some considerations about their 
clinical application in the treatment of acute and chronic soft 
tissue lesions. The improvement of reconstructive techniques 
and regenerative medicine has contributed to reduce, in re-
cent years, the time needed for healing, to decrease the cases 
of non-healing, the number of overall major amputations and 
segmental amputations, thus influencing positively the sub-
sequent costs of temporary or permanent disabilities. An 
Italian observational study has already shown that new 
therapies, using among others, hyaluronic acid, help to re-
duce the lesion (40 vs -34%, p<0.05) and to achieve com-
plete healing in less time than that required using traditional 
dressings; costs also being lower [4, 38]. From these data it 
follows that, although the costs per unit are on average 
higher, the total final cost is beneficial. Our approach, 
probably directing the recruitment of EPC, already induced 
by hypoxic conditions, at the lesion level, promoted in-
creased neoangiogenesis and reduced bacterial infections. 
Limitations to this study are that we did not assess whether 
there is a different LPC treatment efficacy depending on the 
aetiology of the ulcer. Moreover factors released by LPC, 
responsible for improving wound healing, are still not identi-
fied. 
CONCLUSIONS  
 The possibility of improving local perfusion with recon-
structive or restorative surgery of the vascularity of the limb 
becomes the determining factor for clinical success and to 
avoid major amputation. Neoangiogenesis is a prerequisite 
for determining tissue repair: new vessels deliver oxygen to 
the injury site as well as nutrients and humoral factors neces-
sary to allow the healing of the wounds. The intensity and 
the speed of this phenomenon is critical to get the regenera-
tion and then heal wounds. The approach proposed in this 
study appears to meet these requirements and seems to be an 
attractive alternative to traditional methods. In fact, the infil-
tration of leukocytes and platelets stimulates angiogenesis 
even in the early phase of treatment. A significantly higher 
vascular density was observed in the LPC-treated group 
compared with conventional therapy-treated group. The use 
of hyaluronic acid as a scaffold in the gel formulation of the 
"Platelet Rich Plasma" in the activated form undoubtedly 
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helps regeneration but in a later stage only and therefore the 
results obtained in the present study are directly dependent 
on LPC delivered within the wounds.  
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